{"id":19760,"date":"2023-12-12T16:10:13","date_gmt":"2023-12-12T21:10:13","guid":{"rendered":"https:\/\/blogs.cooperhealth.org\/weeklyrounds\/?p=19760"},"modified":"2023-12-12T16:10:13","modified_gmt":"2023-12-12T21:10:13","slug":"md-anderson-cancer-center-at-cooper-first-in-the-world-to-enroll-a-patient-in-a-promising-new-clinical-trial-for-treatment-of-metastatic-melanoma","status":"publish","type":"post","link":"https:\/\/blogs.cooperhealth.org\/weeklyrounds\/2023\/12\/md-anderson-cancer-center-at-cooper-first-in-the-world-to-enroll-a-patient-in-a-promising-new-clinical-trial-for-treatment-of-metastatic-melanoma\/","title":{"rendered":"MD Anderson Cancer Center at Cooper First in the World to Enroll a Patient in a Promising New Clinical Trial for Treatment of Metastatic Melanoma"},"content":{"rendered":"

Researchers at\u00a0MD Anderson Cancer Center at Cooper<\/a>\u00a0are leading the way in new approaches to treating advanced melanoma using tumor infiltrating lymphocyte (TIL) therapy. Earlier this year, MD Anderson at Cooper became the first site in the world to offer and enroll a patient in\u00a0TILVANCE-301<\/a>, a new randomized Phase III clinical trial evaluating the efficacy of TIL therapy as a first-line treatment versus pembrolizumab (current standard of immunotherapy care) for advanced melanoma.<\/p>\n

\u201cTIL therapy is a promising, personalized approach to cancer treatment,\u201d says\u00a0Young Ki Hong, MD, MPH<\/a>, a surgical oncologist at MD Anderson at Cooper, and principal investigator of several TIL studies. \u201cOur patient has had a remarkable response to this therapy. Each subsequent surveillance scan has shown a continuous reduction in the size of her tumor. We are grateful for patients who participate in clinical trials. Through their own treatment, they are helping to advance cancer care for others. As she completes her treatment, we are encouraged not only by her results, but what it means for patients in the future.\u201d<\/p>\n

\u201cResearch findings published in top medical journals, such as the\u00a0New England Journal of Medicine, have shown that TIL therapy not only prolongs the lives of those with advanced melanoma but also allows some to have complete responses, even after failing the previous standard-of-care immunotherapy. Research has documented numerous patients who have been cured of their metastatic melanoma for more than 10 years from this treatment,\u201d Dr. Hong said.<\/p>\n

This clinical trial is part of emerging cell therapy treatments for several types of solid tumor cancers, including non-small cell lung cancer, cervical cancer, and head and neck cancers. Researchers at MD Anderson at Cooper are participating in clinical trials in these areas as well.<\/p>\n

\u00a0<\/strong>How TIL Therapy Works<\/strong><\/p>\n

After treating cancer for long periods, a patient\u2019s T cells often become depleted and no longer effective. TIL therapy replaces these ineffective T cells with the patient\u2019s\u00a0own\u00a0boosted, lab-grown T cells that can renew the fight against the cancer.<\/p>\n

First, a cancerous tumor is removed from the patient and sent to a special lab. At the lab, the patient\u2019s cancer-fighting T cells are isolated from the tumor. They are revitalized, grown into billions of cells, and then frozen.<\/p>\n

When the new T cells are ready, the patient receives intensive chemotherapy treatment to eliminate regulatory cells, which suppress immune response in the body. The boosted, lab-grown T cells are returned to the patient through an infusion. At this point, the only T cells in the patient\u2019s body are their own supercharged cancer-fighting cells. Patients then receive between one and six doses of a medication called IL2, which further boosts effectiveness of the T cells.<\/p>\n

The patient\u2019s new T cells regenerate and form lasting memory cells, which continuously look for and attack new cancer cells.<\/p>\n

For more information about this clinical trial and other cancer clinical trials,\u00a0visit Cooper\u2019s website here<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"

Researchers at\u00a0MD Anderson Cancer Center at Cooper\u00a0are leading the way in new approaches to treating advanced melanoma using tumor infiltrating lymphocyte (TIL) therapy. Earlier this year, MD Anderson at Cooper became the first site in the world to offer and enroll a patient in\u00a0TILVANCE-301, a new randomized Phase III clinical trial evaluating the efficacy of … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":69,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[1],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-mlongshore","4":"post-19760","6":"format-standard","7":"category-uncategorized"},"yoast_head":"\nMD Anderson Cancer Center at Cooper First in the World to Enroll a Patient in a Promising New Clinical Trial for Treatment of Metastatic Melanoma - Weekly Rounds<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MD Anderson Cancer Center at Cooper First in the World to Enroll a Patient in a Promising New Clinical Trial for Treatment of Metastatic Melanoma - Weekly Rounds\" \/>\n<meta property=\"og:description\" content=\"Researchers at\u00a0MD Anderson Cancer Center at Cooper\u00a0are leading the way in new approaches to treating advanced melanoma using tumor infiltrating lymphocyte (TIL) therapy. Earlier this year, MD Anderson at Cooper became the first site in the world to offer and enroll a patient in\u00a0TILVANCE-301, a new randomized Phase III clinical trial evaluating the efficacy of ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/blogs.cooperhealth.org\/weeklyrounds\/2023\/12\/md-anderson-cancer-center-at-cooper-first-in-the-world-to-enroll-a-patient-in-a-promising-new-clinical-trial-for-treatment-of-metastatic-melanoma\/\" \/>\n<meta property=\"og:site_name\" content=\"Weekly Rounds\" \/>\n<meta property=\"article:published_time\" content=\"2023-12-12T21:10:13+00:00\" \/>\n<meta name=\"author\" content=\"mlongshore\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"mlongshore\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/blogs.cooperhealth.org\/weeklyrounds\/2023\/12\/md-anderson-cancer-center-at-cooper-first-in-the-world-to-enroll-a-patient-in-a-promising-new-clinical-trial-for-treatment-of-metastatic-melanoma\/\",\"url\":\"https:\/\/blogs.cooperhealth.org\/weeklyrounds\/2023\/12\/md-anderson-cancer-center-at-cooper-first-in-the-world-to-enroll-a-patient-in-a-promising-new-clinical-trial-for-treatment-of-metastatic-melanoma\/\",\"name\":\"MD Anderson Cancer Center at Cooper First in the World to Enroll a Patient in a Promising New Clinical Trial for Treatment of Metastatic Melanoma - Weekly Rounds\",\"isPartOf\":{\"@id\":\"https:\/\/blogs.cooperhealth.org\/weeklyrounds\/#website\"},\"datePublished\":\"2023-12-12T21:10:13+00:00\",\"author\":{\"@id\":\"https:\/\/blogs.cooperhealth.org\/weeklyrounds\/#\/schema\/person\/f8c47845e3e90c9fb4b009077d362bb9\"},\"breadcrumb\":{\"@id\":\"https:\/\/blogs.cooperhealth.org\/weeklyrounds\/2023\/12\/md-anderson-cancer-center-at-cooper-first-in-the-world-to-enroll-a-patient-in-a-promising-new-clinical-trial-for-treatment-of-metastatic-melanoma\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/blogs.cooperhealth.org\/weeklyrounds\/2023\/12\/md-anderson-cancer-center-at-cooper-first-in-the-world-to-enroll-a-patient-in-a-promising-new-clinical-trial-for-treatment-of-metastatic-melanoma\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/blogs.cooperhealth.org\/weeklyrounds\/2023\/12\/md-anderson-cancer-center-at-cooper-first-in-the-world-to-enroll-a-patient-in-a-promising-new-clinical-trial-for-treatment-of-metastatic-melanoma\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/blogs.cooperhealth.org\/weeklyrounds\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MD Anderson Cancer Center at Cooper First in the World to Enroll a Patient in a Promising New Clinical Trial for Treatment of Metastatic Melanoma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/blogs.cooperhealth.org\/weeklyrounds\/#website\",\"url\":\"https:\/\/blogs.cooperhealth.org\/weeklyrounds\/\",\"name\":\"Weekly Rounds\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/blogs.cooperhealth.org\/weeklyrounds\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/blogs.cooperhealth.org\/weeklyrounds\/#\/schema\/person\/f8c47845e3e90c9fb4b009077d362bb9\",\"name\":\"mlongshore\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/blogs.cooperhealth.org\/weeklyrounds\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e6265d1e4c76710b01a9557a40ba4967e4b3d48c96cbddf672f6956775b23c92?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e6265d1e4c76710b01a9557a40ba4967e4b3d48c96cbddf672f6956775b23c92?s=96&d=mm&r=g\",\"caption\":\"mlongshore\"},\"url\":\"https:\/\/blogs.cooperhealth.org\/weeklyrounds\/author\/mlongshore\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"MD Anderson Cancer Center at Cooper First in the World to Enroll a Patient in a Promising New Clinical Trial for Treatment of Metastatic Melanoma - Weekly Rounds","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"MD Anderson Cancer Center at Cooper First in the World to Enroll a Patient in a Promising New Clinical Trial for Treatment of Metastatic Melanoma - Weekly Rounds","og_description":"Researchers at\u00a0MD Anderson Cancer Center at Cooper\u00a0are leading the way in new approaches to treating advanced melanoma using tumor infiltrating lymphocyte (TIL) therapy. Earlier this year, MD Anderson at Cooper became the first site in the world to offer and enroll a patient in\u00a0TILVANCE-301, a new randomized Phase III clinical trial evaluating the efficacy of ... [Read more...]","og_url":"https:\/\/blogs.cooperhealth.org\/weeklyrounds\/2023\/12\/md-anderson-cancer-center-at-cooper-first-in-the-world-to-enroll-a-patient-in-a-promising-new-clinical-trial-for-treatment-of-metastatic-melanoma\/","og_site_name":"Weekly Rounds","article_published_time":"2023-12-12T21:10:13+00:00","author":"mlongshore","twitter_card":"summary_large_image","twitter_misc":{"Written by":"mlongshore","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/blogs.cooperhealth.org\/weeklyrounds\/2023\/12\/md-anderson-cancer-center-at-cooper-first-in-the-world-to-enroll-a-patient-in-a-promising-new-clinical-trial-for-treatment-of-metastatic-melanoma\/","url":"https:\/\/blogs.cooperhealth.org\/weeklyrounds\/2023\/12\/md-anderson-cancer-center-at-cooper-first-in-the-world-to-enroll-a-patient-in-a-promising-new-clinical-trial-for-treatment-of-metastatic-melanoma\/","name":"MD Anderson Cancer Center at Cooper First in the World to Enroll a Patient in a Promising New Clinical Trial for Treatment of Metastatic Melanoma - Weekly Rounds","isPartOf":{"@id":"https:\/\/blogs.cooperhealth.org\/weeklyrounds\/#website"},"datePublished":"2023-12-12T21:10:13+00:00","author":{"@id":"https:\/\/blogs.cooperhealth.org\/weeklyrounds\/#\/schema\/person\/f8c47845e3e90c9fb4b009077d362bb9"},"breadcrumb":{"@id":"https:\/\/blogs.cooperhealth.org\/weeklyrounds\/2023\/12\/md-anderson-cancer-center-at-cooper-first-in-the-world-to-enroll-a-patient-in-a-promising-new-clinical-trial-for-treatment-of-metastatic-melanoma\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/blogs.cooperhealth.org\/weeklyrounds\/2023\/12\/md-anderson-cancer-center-at-cooper-first-in-the-world-to-enroll-a-patient-in-a-promising-new-clinical-trial-for-treatment-of-metastatic-melanoma\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/blogs.cooperhealth.org\/weeklyrounds\/2023\/12\/md-anderson-cancer-center-at-cooper-first-in-the-world-to-enroll-a-patient-in-a-promising-new-clinical-trial-for-treatment-of-metastatic-melanoma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/blogs.cooperhealth.org\/weeklyrounds\/"},{"@type":"ListItem","position":2,"name":"MD Anderson Cancer Center at Cooper First in the World to Enroll a Patient in a Promising New Clinical Trial for Treatment of Metastatic Melanoma"}]},{"@type":"WebSite","@id":"https:\/\/blogs.cooperhealth.org\/weeklyrounds\/#website","url":"https:\/\/blogs.cooperhealth.org\/weeklyrounds\/","name":"Weekly Rounds","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/blogs.cooperhealth.org\/weeklyrounds\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/blogs.cooperhealth.org\/weeklyrounds\/#\/schema\/person\/f8c47845e3e90c9fb4b009077d362bb9","name":"mlongshore","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/blogs.cooperhealth.org\/weeklyrounds\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/e6265d1e4c76710b01a9557a40ba4967e4b3d48c96cbddf672f6956775b23c92?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e6265d1e4c76710b01a9557a40ba4967e4b3d48c96cbddf672f6956775b23c92?s=96&d=mm&r=g","caption":"mlongshore"},"url":"https:\/\/blogs.cooperhealth.org\/weeklyrounds\/author\/mlongshore\/"}]}},"_links":{"self":[{"href":"https:\/\/blogs.cooperhealth.org\/weeklyrounds\/wp-json\/wp\/v2\/posts\/19760","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.cooperhealth.org\/weeklyrounds\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.cooperhealth.org\/weeklyrounds\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.cooperhealth.org\/weeklyrounds\/wp-json\/wp\/v2\/users\/69"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.cooperhealth.org\/weeklyrounds\/wp-json\/wp\/v2\/comments?post=19760"}],"version-history":[{"count":1,"href":"https:\/\/blogs.cooperhealth.org\/weeklyrounds\/wp-json\/wp\/v2\/posts\/19760\/revisions"}],"predecessor-version":[{"id":19761,"href":"https:\/\/blogs.cooperhealth.org\/weeklyrounds\/wp-json\/wp\/v2\/posts\/19760\/revisions\/19761"}],"wp:attachment":[{"href":"https:\/\/blogs.cooperhealth.org\/weeklyrounds\/wp-json\/wp\/v2\/media?parent=19760"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.cooperhealth.org\/weeklyrounds\/wp-json\/wp\/v2\/categories?post=19760"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.cooperhealth.org\/weeklyrounds\/wp-json\/wp\/v2\/tags?post=19760"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}